Raphael Lievin
Overview
Explore the profile of Raphael Lievin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marouf A, Chaubard S, Lievin R, Michot J, Molinari N, Rossignol J, et al.
Hemasphere
. 2025 Jan;
9(1):e70081.
PMID: 39840381
No abstract available.
2.
Koya J, Tanigawa T, Mizuno K, Kim H, Ito Y, Yuasa M, et al.
Nat Commun
. 2024 Oct;
15(1):9106.
PMID: 39438472
Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus (EBV)-related neoplasm preferentially involving the upper aerodigestive tract. Here we show that NK-cell-specific Trp53 disruption in mice leads to the development of...
3.
Lievin R, Maillard A, Hendel-Chavez H, Krzysiek R, Lancar R, Algarte-Genin M, et al.
Blood Adv
. 2024 Sep;
8(23):6017-6027.
PMID: 39348664
HIV infection is associated with an increased risk of diffuse large B-cell lymphoma (DLBCL). In this prospective study, we analyzed the evolution of B-cell activating cytokines (interleukin-6 [IL-6], IL-10, and...
4.
Ito Y, Marouf A, Kogure Y, Koya J, Lievin R, Bruneau J, et al.
Cancer Res
. 2024 Apr;
84(13):2181-2201.
PMID: 38657099
Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus (EBV)-related neoplasm with male dominance and a poor prognosis. A better understanding of the genetic alterations and their functional roles in ENKTCL...
5.
Aiello T, Salmanton-Garcia J, Marchesi F, Weinbergerova B, Glenthoj A, van Praet J, et al.
Haematologica
. 2024 Apr;
109(8):2693-2700.
PMID: 38572549
No abstract available.
6.
Salmanton-Garcia J, Marchesi F, Farina F, Weinbergerova B, Itri F, Davila-Valls J, et al.
EClinicalMedicine
. 2024 Mar;
71:102553.
PMID: 38533127
Background: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals,...
7.
van Doesum J, Salmanton-Garcia J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A, et al.
Blood Adv
. 2023 Apr;
7(11):2645-2655.
PMID: 37058479
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown...
8.
Pagano L, Salmanton-Garcia J, Marchesi F, Blennow O, Gomes Da Silva M, Glenthoj A, et al.
Blood
. 2022 Sep;
140(26):2773-2787.
PMID: 36126318
Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2...
9.
Blennow O, Salmanton-Garcia J, Nowak P, Itri F, van Doesum J, Lopez-Garcia A, et al.
Am J Hematol
. 2022 Jun;
97(8):E312-E317.
PMID: 35702878
No abstract available.
10.
Lievin R, Di Blasi R, Morin F, Galli E, Allain V, De Jorna R, et al.
Bone Marrow Transplant
. 2022 Jan;
57(3):431-439.
PMID: 35094012
Chimeric Antigen Receptor T cells (CAR-T) are an outbreaking treatment option for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)...